Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00309504
First received: March 31, 2006
Last updated: March 30, 2012
Last verified: March 2012
  Purpose

The purpose of this study is to find ways to improve the appearance of tumours or markers that indicate the presence of tumours in Magnetic Resonance Imaging (MRI). Although based on the same technology, there are many ways to obtain images using MRI. The type of image that will be produced by the scanner depends on the instructions sent to the machine. These instructions tell different components of the machine when to turn on and off and all together are called a pulse sequence. These pulse sequences can get quite lengthy and intricate and small changes in them can produce considerable changes in the resulting image. the aim of this protocol is to alter existing pulse sequences to improve image appearance. This protocol will involve only healthy volunteers.


Condition
Healthy

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 40
Study Start Date: March 2006
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Local Healthy volunteers

Criteria

Inclusion Criteria:

  • healthy adult

Exclusion Criteria:

  • subject under 18 years of age
  • subject pregnant, or may be pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00309504

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: Gino B. Fallone, PhD, FCCPH, DABR AHS Cancer Control Alberta
  More Information

No publications provided

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00309504     History of Changes
Other Study ID Numbers: 22307
Study First Received: March 31, 2006
Last Updated: March 30, 2012
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
magnetic resonance imaging
magnetic resonance spectroscopy

ClinicalTrials.gov processed this record on August 21, 2014